The U.S. Food and Drug Administration granted premarket approval for Artivion’s NEXUS® Aortic Arch System on April 7 2026. The NEXUS system is a branched endovascular stent graft developed by Endospan Ltd., designed to treat chronic aortic dissections and aneurysms that previously had limited minimally invasive options. The approval removes a key regulatory hurdle and positions Artivion to capture a $150 million U.S. market for chronic aortic arch disease, complementing its existing AMDS and On‑X platforms.
Clinical data from the NEXUS TRIOMPHE IDE trial underpin the approval. The study reported 90 % patient survival from lesion‑related death, 90 % freedom from disabling stroke at one year, and 98 % freedom from reintervention due to endoleaks. These outcomes demonstrate the system’s safety and effectiveness, giving clinicians confidence to adopt a minimally invasive alternative to open‑chest surgery for a patient group that has historically faced high procedural risk.
The approval also triggers Artivion’s option to acquire Endospan within 90 days of the notice. The company has secured a $150 million delayed‑draw term loan to fund the potential purchase, with an upfront payment of $135 million net of prior payments and loans and an additional earn‑out component. The acquisition would integrate Endospan’s technology and long‑standing partnership, expanding Artivion’s aortic disease portfolio and strengthening its competitive position against rivals such as Gore.
Artivion’s recent financial performance underscores the strategic value of the NEXUS approval. In Q4 2025, GAAP revenue rose to $116.0 million, an 18 % year‑over‑year increase from $97.3 million in Q4 2024, while full‑year 2025 revenue reached $441.3 million, up 13 % from $388.5 million in 2024. Adjusted EBITDA grew 29 % to $22.7 million in Q4 2025 and 26 % to $89.6 million for the full year, reflecting strong execution in the stent graft and On‑X valve segments.
CEO Pat Mackin highlighted the significance of the approval, stating, “NEXUS receiving FDA approval ahead of our expectations is an exciting milestone for patients with aortic arch disease, for our partner Endospan, and for Artivion.” He added that the company has proactively secured financing to support the potential acquisition and is moving diligently to finalize the option. The approval, combined with robust financial results, positions Artivion to accelerate growth in a high‑need therapeutic area and to capitalize on a sizable U.S. and global market opportunity of $600 million.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.